{"success":true,"data":{"pressRelease":{"id":"140531","rtpr_id":"nPn7mpMB2a-20260910","ticker":"SASY","exchange":"Euronext Paris","all_tickers":["SASY"],"title":"Sanofi partners with USA Pickleball to launch \"Serve Up Protection\" campaign to help protect older adults from COVID-19 with NUVAXOVID™","author":"PR Newswire","published_at":"2026-09-10T13:05:47.156Z","article_body":"Sanofi partners with USA Pickleball to launch \"Serve Up Protection\" campaign to help protect older adults from COVID-19 with NUVAXOVID™\n\nPR Newswire\n\nMORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026\n\n * Despite their risk of serious illness from COVID-19, nearly 70% of adults 65\nand older remain unvaccinated, in part due to concerns about potential side\neffects\n * The campaign serves up COVID-19 prevention education, including details about\nNUVAXOVID™ and its established tolerability\nMORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi\nand USA Pickleball are teaming up to launch \"Serve Up Protection,\" a campaign\nto educate older adults about COVID-19 and NUVAXOVID (COVID-19 Vaccine,\nAdjuvanted), the only protein-based, non-mRNA COVID-19 vaccine approved by the\nUS Food and Drug Administration (FDA). \"Serve Up Protection\" aims to reach\npeople during the respiratory season on and off the court using multimedia\neducation, trusted pickleball voices and fan experiences at major events,\nincluding USA Pickleball's National Championships\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=4028487711&u=https%3A%2F%2Fusapickleballnationals.com%2F&a=National+Championships)\n in November in San Diego.\n\nOlder adults are staying active with the help of sports such as pickleball,\nbut age-related changes to the immune system and health conditions like\nchronic lung disease, cardiovascular disease and diabetes, can increase their\nrisk of serious illness from COVID-19. Despite these risks, many adults 65 and\nolder remain unvaccinated, driven by factors such as uncertainty about\nevolving health guidance and concerns about side effects.\n\n\"Concerns about potential vaccine side effects can be a barrier to vaccination\nfor older adults, who don't want disruption in their daily lives and hobbies,\"\nsaid Sriram Jambunathan, Head of Marketing & Commercial Strategy, US\nVaccines at Sanofi. \"By teaming up with USA Pickleball on 'Serve Up\nProtection,' we're educating older adults that NUVAXOVID can help provide\npowerful protection against COVID-19 with manageable side effects.\"\n\n\"At USA Pickleball, we're committed to creating meaningful partnerships that\nhelp our community enjoy the sport for years to come,\" said Christian Portaro,\nVice President of Partnerships at USA Pickleball. \"As pickleball continues to\nattract players of all ages, we're proud to work with Sanofi on the 'Serve Up\nProtection' campaign to provide education and resources that empower\nindividuals to make informed decisions about their health. By helping players\nbetter understand risk and prevention options, we're supporting their ability\nto stay active, connected and on the court.\"\n\nIn two pivotal phase 3 studies, NUVAXOVID demonstrated high efficacy against\nCOVID-19 and the majority of side effects were mild to moderate and would not\nprevent daily activities, according to FDA grading. Rare, serious side effects\nare possible. Please see Important Safety Information below.\n\nTalk to your doctor or pharmacist to learn more about if NUVAXOVID may be\nright for you. Visit NUVAXOVID.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=3561783335&u=https%3A%2F%2Fwww.nuvaxovid.com%2F&a=NUVAXOVID.com)\n for more information and to find a vaccine near you\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=3759022857&u=https%3A%2F%2Fwww.nuvaxovid.com%2Fvaccine-locator&a=vaccine+near+you)\n.\n\nAbout NUVAXOVID\nNUVAXOVID is a protein-based, adjuvanted vaccine for active immunization to\nprevent COVID-19 caused by SARS-CoV-2. It is developed using recombinant\ntechnology, an established platform with a long track record across multiple\nvaccine types.\n\nHaving multiple vaccine options becomes increasingly important for sustainable\npublic health strategies. NUVAXOVID has an established safety and tolerability\nprofile. Nuvaxovid is a protein-based vaccine option that healthcare systems\ncan add to their routine vaccination programs. Offering a range of vaccine\ntypes might aid healthcare systems in addressing vaccine hesitancy.\n\nNUVAXOVID was originally licensed by Novavax. Sanofi is now market\nauthorization holder for NUVAXOVID in the US, the EU and the United Kingdom.\nBuilding on its commercial launch in the US, Taiwan, and Morocco in 2025,\nSanofi is expanding NUVAXOVID's availability to additional markets - including\nthe United Kingdom, Germany, and Canada - from 2026 onwards.\n\nIndication\nNUVAXOVID is a vaccine to protect against COVID-19 for people who are:\n\n * 65 years of age and older, or\n * 12 years through 64 years of age at high risk for severe COVID-19\nVaccination with NUVAXOVID may not protect all people who receive the vaccine.\n\nNUVAXOVID does not contain SARS-CoV-2, the virus that\ncauses COVID-19. NUVAXOVID cannot give you or your child COVID-19.\n\nImportant Safety Information\nYou or your child should not get NUVAXOVID if you had a severe allergic\nreaction to a previous dose of NUVAXOVID or to any of its ingredients.\n\nThere is a remote chance that the vaccine could cause a severe allergic\nreaction, which would usually occur within a few minutes to one hour after\ngetting a dose. For this reason, the vaccination provider may ask you or your\nchild to stay at the place where you or your child received the vaccine for\nmonitoring after vaccination. Signs of a severe allergic reaction can include:\ndifficulty breathing, swelling of the face and throat, a fast heartbeat, a bad\nrash all over the body and/or dizziness and weakness\n\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation\nof the lining outside the heart) have occurred in some people who have\nreceived NUVAXOVID. The chance of having this occur is very low. You should\nseek medical attention right away if you or your child have any of the\nfollowing symptoms after receiving the vaccine: chest pain; shortness of\nbreath; feelings of having a fast-beating, fluttering, or pounding heart.\n\nOther side effects reported in clinical trials and/or post-approval use of\nNUVAXOVID include: Injection site reactions (pain/tenderness, swelling,\nredness and itching), fatigue or generally feeling unwell, muscle pain,\nheadache, joint pain, nausea, vomiting, fever, chills, allergic reactions such\nas hives and swelling of the face, swollen lymph nodes, paresthesia (unusual\nfeeling in the skin such as tingling or a crawling feeling), and hypoesthesia\n(decreased feeling or sensitivity, especially in the skin)\n\nPlease see full Prescribing Information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=2639418545&u=https%3A%2F%2Fwww.vaccineshoppe.com%2Fassets%2Fpdf%2Fvsh%2Fpi%2FNuvaxovidPI.pdf&a=Prescribing+Information)\n, including Patient Information, for more details.\n\nAbout COVID-19\nCoronavirus disease (COVID-19) is an infectious disease caused by the\nSARS-CoV-2 virus. Most people infected with the virus will experience mild to\nmoderate respiratory illness and recover without requiring special treatment.\nHowever, some will become seriously ill resulting in hospitalization and\ndeath.\n\nThe disease not only causes immediate health impacts but also increases the\nlong-term risk of cardiovascular complications, including heart attacks and\nstrokes, and older adults hospitalized for COVID-19 face substantially higher\nmortality risk than those hospitalized for influenza. Older adults and those\nwith chronic conditions - including cardiovascular disease, chronic lung\ndisease, diabetes, and obesity - face the highest risk of severe illness. In\nthe US, an estimated 74% of adults have at least one such risk factor,\nunderscoring the scale of the vulnerable population that stands to benefit\nfrom effective and well-tolerated COVID-19 vaccination.\n\nMAT-US-2608280-v1.0-08/2026\n\nAbout Sanofi\nSanofi\nis an R&D driven, AI-powered biopharma company committed to improving people's lives\nand delivering compelling growth. We apply our deep understanding of the\nimmune system to invent medicines and vaccines that treat and protect millions\nof people around the world, with an innovative pipeline that could benefit\nmillions more. Our team is guided by one purpose: we chase the miracles\nof science to improve people's lives; this inspires us to drive progress and\ndeliver positive impact for our people and the communities we serve, by\naddressing the most urgent healthcare, environmental, and societal challenges\nof our time.\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY\n\nAbout USA Pickleball\nUSA Pickleball is the official National Governing Body (NGB) for the sport of\npickleball in the United States. As a nonprofit 501(c)(3) organization, USA\nPickleball is dedicated to preserving the integrity of the game while\nadvancing its growth and development nationwide. The organization supports\nplayers, clubs, and communities by sanctioning premier tournaments, offering\ncertified equipment testing, training referees, certifying facilities, and\nproviding a wide range of educational resources. USA Pickleball also maintains\nand updates the official rules of the sport, ensuring consistency and fairness\nat every level of play. Led by a Board of Directors and a dedicated national\noffice staff, USA Pickleball delivers the infrastructure and strategic vision\nnecessary to fuel the continued expansion of pickleball across the\ncountry—benefiting members with exclusive access to events, programs, and\ntools that elevate their experience on and off the court.\n\nMedia Relations\nSandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com\n(mailto:sandrine.guendoul@sanofi.com)\nEvan Berland | +1 215 432 0234 | evan.berland@sanofi.com\n(mailto:evan.berland@sanofi.com)\nLéo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com\n(mailto:leo.lebourhis@sanofi.com)\nVictor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com\n(mailto:victor.rouault@sanofi.com)\nTimothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com\n(mailto:timothy.gilbert@sanofi.com)\nLéa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com\n(mailto:lea.ubaldi@sanofi.com)\nEkaterina Pesheva | +1 410 926 6780 | ekaterina.pescheva@sanofi.com\n(mailto:ekaterina.pescheva@sanofi.com)\n\nInvestor Relations\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com\n(mailto:thomas.larsen@sanofi.com)\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com\n(mailto:alize.kaisserian@sanofi.com)\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com\n(mailto:keita.browne@sanofi.com)\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com\n(mailto:nathalie.pham@sanofi.com)\nNina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com\n(mailto:nina.goworek@sanofi.com)\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com\n(mailto:thibaud.chatelet@sanofi.com)\nYun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com (mailto:yun.li3@sanofi.com)\n\nSanofi forward-looking statements\nThis media update contains forward-looking statements within the meaning of\napplicable securities laws, including the Private Securities Litigation Reform\nAct of 1995, as amended.\n\nForward-looking statements are statements that are not historical facts. These\nstatements include projections and estimates and their underlying assumptions\nregarding the marketing and other potential of the product; regarding\npotential future events and revenues from the product.  Words such as\n\"expect,\" \"anticipate,\" \"believe,\" \"intend,\" \"estimate,\" \"plan,\" \"can,\"\n\"contemplate,\" \"could,\" \"is designed to,\" \"may,\" \"might,\" \"potential,\"\n\"objective,\" \"attempt,\" \"target,\" \"project,\" \"strategy,\" \"strive,\" \"desire,\"\n\"predict,\" \"forecast,\" \"ambition,\" \"guideline,\" \"seek,\" \"should,\" \"will,\"\n\"goal,\"  or the negative of these and similar expressions are intended to\nidentify forward-looking statements.\n\nAlthough Sanofi's management believes that the expectations reflected in such\nforward-looking statements are reasonable, investors are cautioned that\nforward-looking information and statements are subject to various risks and\nuncertainties, many of which are difficult to predict and generally beyond the\ncontrol of Sanofi, that could cause actual results and developments to differ\nmaterially from those expressed in, or implied or projected by, the\nforward-looking information and statements. These risks, uncertainties and\nassumptions include among other things, unexpected regulatory actions or\ndelays, or government regulation generally, that could affect the availability\nor commercial potential of the product, the fact that product may not be\ncommercially successful; authorities' decisions regarding whether and when to\napprove a product candidate; political pressure in the United States to\nmandate lower drug prices including \"most favored nation\" pricing for State\nMedicaid programs; the uncertainties inherent in research and development,\nincluding future clinical data and analysis of existing clinical data relating\nto the product, including post marketing, unexpected safety, quality or\nmanufacturing issues; competition in general; risks associated with\nintellectual property and any related pending or future litigation and the\nultimate outcome of such litigation, and volatile economic and market\nconditions, and the impact that global crises may have on us, our customers,\nsuppliers, vendors, and other business partners, and the financial condition\nof any one of them, as well as on our employees and on the global economy as a\nwhole. The risks and uncertainties also include the uncertainties discussed or\nidentified in the public filings with the SEC and the French Markets Authority\n(AMF) made by Sanofi, including those listed under \"Risk Factors\" and\n\"Cautionary Statement Regarding Forward-Looking Statements\" in Sanofi's annual\nreport on Form 20-F for the year ended December 31, 2025 or contained in our\nperiodic reports on Form 6-K. Other than as required by applicable law, Sanofi\ndoes not undertake any obligation to update or revise any forward-looking\ninformation or statements. In light of these risks, uncertainties and\nassumptions, you should not place undue reliance on any forward-looking\nstatements contained herein.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/sanofi-partners-with-usa-pickleball-to-launch-serve-up-protection-campaign-to-help-protect-older-adults-from-covid-19-with-nuvaxovid-302875345.html\n(https://www.prnewswire.com/news-releases/sanofi-partners-with-usa-pickleball-to-launch-serve-up-protection-campaign-to-help-protect-older-adults-from-covid-19-with-nuvaxovid-302875345.html)\n\nSOURCE USA Pickleball\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1953147/USA-Pickleball-Logo.jpg?id=OA2940535\nhttps://mmx.prnewswire.com/media/MS1985723/Sanofi-Logo.jpg?id=OA2941240\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7mpMB2a-20260910","title":"Sanofi partners with USA Pickleball to launch \"Serve Up Protection\" campaign to help protect older adults from COVID-19 with NUVAXOVID™","author":"PR Newswire","ticker":"SASY","created":"2026-09-10T13:05:47.156Z","tickers":["SASY"],"exchange":"Euronext Paris","article_body":"Sanofi partners with USA Pickleball to launch \"Serve Up Protection\" campaign to help protect older adults from COVID-19 with NUVAXOVID™\n\nPR Newswire\n\nMORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026\n\n * Despite their risk of serious illness from COVID-19, nearly 70% of adults 65\nand older remain unvaccinated, in part due to concerns about potential side\neffects\n * The campaign serves up COVID-19 prevention education, including details about\nNUVAXOVID™ and its established tolerability\nMORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi\nand USA Pickleball are teaming up to launch \"Serve Up Protection,\" a campaign\nto educate older adults about COVID-19 and NUVAXOVID (COVID-19 Vaccine,\nAdjuvanted), the only protein-based, non-mRNA COVID-19 vaccine approved by the\nUS Food and Drug Administration (FDA). \"Serve Up Protection\" aims to reach\npeople during the respiratory season on and off the court using multimedia\neducation, trusted pickleball voices and fan experiences at major events,\nincluding USA Pickleball's National Championships\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=4028487711&u=https%3A%2F%2Fusapickleballnationals.com%2F&a=National+Championships)\n in November in San Diego.\n\nOlder adults are staying active with the help of sports such as pickleball,\nbut age-related changes to the immune system and health conditions like\nchronic lung disease, cardiovascular disease and diabetes, can increase their\nrisk of serious illness from COVID-19. Despite these risks, many adults 65 and\nolder remain unvaccinated, driven by factors such as uncertainty about\nevolving health guidance and concerns about side effects.\n\n\"Concerns about potential vaccine side effects can be a barrier to vaccination\nfor older adults, who don't want disruption in their daily lives and hobbies,\"\nsaid Sriram Jambunathan, Head of Marketing & Commercial Strategy, US\nVaccines at Sanofi. \"By teaming up with USA Pickleball on 'Serve Up\nProtection,' we're educating older adults that NUVAXOVID can help provide\npowerful protection against COVID-19 with manageable side effects.\"\n\n\"At USA Pickleball, we're committed to creating meaningful partnerships that\nhelp our community enjoy the sport for years to come,\" said Christian Portaro,\nVice President of Partnerships at USA Pickleball. \"As pickleball continues to\nattract players of all ages, we're proud to work with Sanofi on the 'Serve Up\nProtection' campaign to provide education and resources that empower\nindividuals to make informed decisions about their health. By helping players\nbetter understand risk and prevention options, we're supporting their ability\nto stay active, connected and on the court.\"\n\nIn two pivotal phase 3 studies, NUVAXOVID demonstrated high efficacy against\nCOVID-19 and the majority of side effects were mild to moderate and would not\nprevent daily activities, according to FDA grading. Rare, serious side effects\nare possible. Please see Important Safety Information below.\n\nTalk to your doctor or pharmacist to learn more about if NUVAXOVID may be\nright for you. Visit NUVAXOVID.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=3561783335&u=https%3A%2F%2Fwww.nuvaxovid.com%2F&a=NUVAXOVID.com)\n for more information and to find a vaccine near you\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=3759022857&u=https%3A%2F%2Fwww.nuvaxovid.com%2Fvaccine-locator&a=vaccine+near+you)\n.\n\nAbout NUVAXOVID\nNUVAXOVID is a protein-based, adjuvanted vaccine for active immunization to\nprevent COVID-19 caused by SARS-CoV-2. It is developed using recombinant\ntechnology, an established platform with a long track record across multiple\nvaccine types.\n\nHaving multiple vaccine options becomes increasingly important for sustainable\npublic health strategies. NUVAXOVID has an established safety and tolerability\nprofile. Nuvaxovid is a protein-based vaccine option that healthcare systems\ncan add to their routine vaccination programs. Offering a range of vaccine\ntypes might aid healthcare systems in addressing vaccine hesitancy.\n\nNUVAXOVID was originally licensed by Novavax. Sanofi is now market\nauthorization holder for NUVAXOVID in the US, the EU and the United Kingdom.\nBuilding on its commercial launch in the US, Taiwan, and Morocco in 2025,\nSanofi is expanding NUVAXOVID's availability to additional markets - including\nthe United Kingdom, Germany, and Canada - from 2026 onwards.\n\nIndication\nNUVAXOVID is a vaccine to protect against COVID-19 for people who are:\n\n * 65 years of age and older, or\n * 12 years through 64 years of age at high risk for severe COVID-19\nVaccination with NUVAXOVID may not protect all people who receive the vaccine.\n\nNUVAXOVID does not contain SARS-CoV-2, the virus that\ncauses COVID-19. NUVAXOVID cannot give you or your child COVID-19.\n\nImportant Safety Information\nYou or your child should not get NUVAXOVID if you had a severe allergic\nreaction to a previous dose of NUVAXOVID or to any of its ingredients.\n\nThere is a remote chance that the vaccine could cause a severe allergic\nreaction, which would usually occur within a few minutes to one hour after\ngetting a dose. For this reason, the vaccination provider may ask you or your\nchild to stay at the place where you or your child received the vaccine for\nmonitoring after vaccination. Signs of a severe allergic reaction can include:\ndifficulty breathing, swelling of the face and throat, a fast heartbeat, a bad\nrash all over the body and/or dizziness and weakness\n\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation\nof the lining outside the heart) have occurred in some people who have\nreceived NUVAXOVID. The chance of having this occur is very low. You should\nseek medical attention right away if you or your child have any of the\nfollowing symptoms after receiving the vaccine: chest pain; shortness of\nbreath; feelings of having a fast-beating, fluttering, or pounding heart.\n\nOther side effects reported in clinical trials and/or post-approval use of\nNUVAXOVID include: Injection site reactions (pain/tenderness, swelling,\nredness and itching), fatigue or generally feeling unwell, muscle pain,\nheadache, joint pain, nausea, vomiting, fever, chills, allergic reactions such\nas hives and swelling of the face, swollen lymph nodes, paresthesia (unusual\nfeeling in the skin such as tingling or a crawling feeling), and hypoesthesia\n(decreased feeling or sensitivity, especially in the skin)\n\nPlease see full Prescribing Information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4771194-1&h=2639418545&u=https%3A%2F%2Fwww.vaccineshoppe.com%2Fassets%2Fpdf%2Fvsh%2Fpi%2FNuvaxovidPI.pdf&a=Prescribing+Information)\n, including Patient Information, for more details.\n\nAbout COVID-19\nCoronavirus disease (COVID-19) is an infectious disease caused by the\nSARS-CoV-2 virus. Most people infected with the virus will experience mild to\nmoderate respiratory illness and recover without requiring special treatment.\nHowever, some will become seriously ill resulting in hospitalization and\ndeath.\n\nThe disease not only causes immediate health impacts but also increases the\nlong-term risk of cardiovascular complications, including heart attacks and\nstrokes, and older adults hospitalized for COVID-19 face substantially higher\nmortality risk than those hospitalized for influenza. Older adults and those\nwith chronic conditions - including cardiovascular disease, chronic lung\ndisease, diabetes, and obesity - face the highest risk of severe illness. In\nthe US, an estimated 74% of adults have at least one such risk factor,\nunderscoring the scale of the vulnerable population that stands to benefit\nfrom effective and well-tolerated COVID-19 vaccination.\n\nMAT-US-2608280-v1.0-08/2026\n\nAbout Sanofi\nSanofi\nis an R&D driven, AI-powered biopharma company committed to improving people's lives\nand delivering compelling growth. We apply our deep understanding of the\nimmune system to invent medicines and vaccines that treat and protect millions\nof people around the world, with an innovative pipeline that could benefit\nmillions more. Our team is guided by one purpose: we chase the miracles\nof science to improve people's lives; this inspires us to drive progress and\ndeliver positive impact for our people and the communities we serve, by\naddressing the most urgent healthcare, environmental, and societal challenges\nof our time.\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY\n\nAbout USA Pickleball\nUSA Pickleball is the official National Governing Body (NGB) for the sport of\npickleball in the United States. As a nonprofit 501(c)(3) organization, USA\nPickleball is dedicated to preserving the integrity of the game while\nadvancing its growth and development nationwide. The organization supports\nplayers, clubs, and communities by sanctioning premier tournaments, offering\ncertified equipment testing, training referees, certifying facilities, and\nproviding a wide range of educational resources. USA Pickleball also maintains\nand updates the official rules of the sport, ensuring consistency and fairness\nat every level of play. Led by a Board of Directors and a dedicated national\noffice staff, USA Pickleball delivers the infrastructure and strategic vision\nnecessary to fuel the continued expansion of pickleball across the\ncountry—benefiting members with exclusive access to events, programs, and\ntools that elevate their experience on and off the court.\n\nMedia Relations\nSandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com\n(mailto:sandrine.guendoul@sanofi.com)\nEvan Berland | +1 215 432 0234 | evan.berland@sanofi.com\n(mailto:evan.berland@sanofi.com)\nLéo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com\n(mailto:leo.lebourhis@sanofi.com)\nVictor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com\n(mailto:victor.rouault@sanofi.com)\nTimothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com\n(mailto:timothy.gilbert@sanofi.com)\nLéa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com\n(mailto:lea.ubaldi@sanofi.com)\nEkaterina Pesheva | +1 410 926 6780 | ekaterina.pescheva@sanofi.com\n(mailto:ekaterina.pescheva@sanofi.com)\n\nInvestor Relations\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com\n(mailto:thomas.larsen@sanofi.com)\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com\n(mailto:alize.kaisserian@sanofi.com)\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com\n(mailto:keita.browne@sanofi.com)\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com\n(mailto:nathalie.pham@sanofi.com)\nNina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com\n(mailto:nina.goworek@sanofi.com)\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com\n(mailto:thibaud.chatelet@sanofi.com)\nYun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com (mailto:yun.li3@sanofi.com)\n\nSanofi forward-looking statements\nThis media update contains forward-looking statements within the meaning of\napplicable securities laws, including the Private Securities Litigation Reform\nAct of 1995, as amended.\n\nForward-looking statements are statements that are not historical facts. These\nstatements include projections and estimates and their underlying assumptions\nregarding the marketing and other potential of the product; regarding\npotential future events and revenues from the product.  Words such as\n\"expect,\" \"anticipate,\" \"believe,\" \"intend,\" \"estimate,\" \"plan,\" \"can,\"\n\"contemplate,\" \"could,\" \"is designed to,\" \"may,\" \"might,\" \"potential,\"\n\"objective,\" \"attempt,\" \"target,\" \"project,\" \"strategy,\" \"strive,\" \"desire,\"\n\"predict,\" \"forecast,\" \"ambition,\" \"guideline,\" \"seek,\" \"should,\" \"will,\"\n\"goal,\"  or the negative of these and similar expressions are intended to\nidentify forward-looking statements.\n\nAlthough Sanofi's management believes that the expectations reflected in such\nforward-looking statements are reasonable, investors are cautioned that\nforward-looking information and statements are subject to various risks and\nuncertainties, many of which are difficult to predict and generally beyond the\ncontrol of Sanofi, that could cause actual results and developments to differ\nmaterially from those expressed in, or implied or projected by, the\nforward-looking information and statements. These risks, uncertainties and\nassumptions include among other things, unexpected regulatory actions or\ndelays, or government regulation generally, that could affect the availability\nor commercial potential of the product, the fact that product may not be\ncommercially successful; authorities' decisions regarding whether and when to\napprove a product candidate; political pressure in the United States to\nmandate lower drug prices including \"most favored nation\" pricing for State\nMedicaid programs; the uncertainties inherent in research and development,\nincluding future clinical data and analysis of existing clinical data relating\nto the product, including post marketing, unexpected safety, quality or\nmanufacturing issues; competition in general; risks associated with\nintellectual property and any related pending or future litigation and the\nultimate outcome of such litigation, and volatile economic and market\nconditions, and the impact that global crises may have on us, our customers,\nsuppliers, vendors, and other business partners, and the financial condition\nof any one of them, as well as on our employees and on the global economy as a\nwhole. The risks and uncertainties also include the uncertainties discussed or\nidentified in the public filings with the SEC and the French Markets Authority\n(AMF) made by Sanofi, including those listed under \"Risk Factors\" and\n\"Cautionary Statement Regarding Forward-Looking Statements\" in Sanofi's annual\nreport on Form 20-F for the year ended December 31, 2025 or contained in our\nperiodic reports on Form 6-K. Other than as required by applicable law, Sanofi\ndoes not undertake any obligation to update or revise any forward-looking\ninformation or statements. In light of these risks, uncertainties and\nassumptions, you should not place undue reliance on any forward-looking\nstatements contained herein.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/sanofi-partners-with-usa-pickleball-to-launch-serve-up-protection-campaign-to-help-protect-older-adults-from-covid-19-with-nuvaxovid-302875345.html\n(https://www.prnewswire.com/news-releases/sanofi-partners-with-usa-pickleball-to-launch-serve-up-protection-campaign-to-help-protect-older-adults-from-covid-19-with-nuvaxovid-302875345.html)\n\nSOURCE USA Pickleball\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1953147/USA-Pickleball-Logo.jpg?id=OA2940535\nhttps://mmx.prnewswire.com/media/MS1985723/Sanofi-Logo.jpg?id=OA2941240\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-10T13:05:47.196817102Z","server_sent_at_ms":1789045547196},"received_at":"2026-09-10T13:05:47.359Z","source_url":"https://www.prnewswire.com/news-releases/sanofi-partners-with-usa-pickleball-to-launch-serve-up-protection-campaign-to-help-protect-older-adults-from-covid-19-with-nuvaxovid-302875345.html"},"analysis":{"id":"129369","press_release_id":"140531","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["No financial terms or uptake targets disclosed; campaign impact on NUVAXOVID sales is unquantified","Campaign messaging emphasizes tolerability while the label carries myocarditis/pericarditis warnings and a 'may not protect all people' limitation"],"eventType":"partnership","narrative":"Sanofi and USA Pickleball are launching the \"Serve Up Protection\" campaign to educate older adults about COVID-19 and NUVAXOVID, the only protein-based, non-mRNA COVID-19 vaccine approved by the FDA.\n\nThe campaign targets a persistent vaccination gap: nearly 70% of US adults 65 and older remain unvaccinated against COVID-19, with concerns about side effects cited as a key barrier. Activations run through respiratory season, including fan experiences at USA Pickleball's National Championships in San Diego in November.\n\nNUVAXOVID was originally licensed by Novavax, with Sanofi now the market authorization holder in the US, EU and UK; Sanofi launched the shot in the US, Taiwan and Morocco in 2025 and is expanding to the UK, Germany and Canada from 2026 onwards.\n\nNo financial terms were disclosed, so this reads as a modest seasonal commercial tailwind for Sanofi's vaccines franchise rather than a market-moving event.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Sanofi leans on pickleball culture to chip away at senior vaccine hesitancy for the only FDA-approved non-mRNA COVID-19 shot."},"keyFigures":{"drugName":"NUVAXOVID (COVID-19 Vaccine, Adjuvanted)","phaseOfTrial":"Phase 3 (two pivotal studies)","customDimensions":{"older_adults_unvaccinated_pct":"nearly 70%","us_adults_with_risk_factor_pct":"74%"}},"quotedText":"\"Concerns about potential vaccine side effects can be a barrier to vaccination\nfor older adults, who don't want disruption in their daily lives and hobbies,\"","namedEntities":{"people":[{"name":"Sriram Jambunathan","role":"Head of Marketing & Commercial Strategy, US Vaccines at Sanofi"},{"name":"Christian Portaro","role":"Vice President of Partnerships at USA Pickleball"}],"products":["NUVAXOVID (COVID-19 Vaccine, Adjuvanted)","Serve Up Protection campaign"],"companies":[{"name":"Sanofi","ticker":"SNY","relationship":"issuer / campaign sponsor (filer brand)"},{"name":"USA Pickleball","relationship":"campaign partner; nonprofit national governing body for pickleball"},{"name":"Novavax","relationship":"original licensor of NUVAXOVID; Sanofi is now market authorization holder"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"This is a co-marketing/education campaign supporting an already FDA-approved vaccine (NUVAXOVID) ahead of respiratory season -- a modest commercial tailwind, not a binary or financial event. No revenue figures, guidance, or deal terms are disclosed."},"tickerRelevance":{"others":[{"ticker":"SNY","relevance":"Sanofi NASDAQ ADR listing -- issuer of the campaign"},{"ticker":"SAN","relevance":"Sanofi EURONEXT Paris listing -- issuer of the campaign"}],"primary":"SASY"},"globalImportance":15,"audienceRelevance":30,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"mega-cap pharma (trades as SAN/SNY)","eventGravity":"marketing/education campaign","financialTerms":"none disclosed","issuerAuthored":true,"commercialRelevance":"supports seasonal NUVAXOVID uptake among 65+ cohort","householdBrandBoost":"Sanofi is a household pharma name; COVID/vaccine topic has retail follow-through"}},"event_type":"partnership","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":2,"narrative":"Sanofi and USA Pickleball are launching the \"Serve Up Protection\" campaign to educate older adults about COVID-19 and NUVAXOVID, the only protein-based, non-mRNA COVID-19 vaccine approved by the FDA.\n\nThe campaign targets a persistent vaccination gap: nearly 70% of US adults 65 and older remain unvaccinated against COVID-19, with concerns about side effects cited as a key barrier. Activations run through respiratory season, including fan experiences at USA Pickleball's National Championships in San Diego in November.\n\nNUVAXOVID was originally licensed by Novavax, with Sanofi now the market authorization holder in the US, EU and UK; Sanofi launched the shot in the US, Taiwan and Morocco in 2025 and is expanding to the UK, Germany and Canada from 2026 onwards.\n\nNo financial terms were disclosed, so this reads as a modest seasonal commercial tailwind for Sanofi's vaccines franchise rather than a market-moving event.","key_figures":{"drugName":"NUVAXOVID (COVID-19 Vaccine, Adjuvanted)","phaseOfTrial":"Phase 3 (two pivotal studies)","customDimensions":{"older_adults_unvaccinated_pct":"nearly 70%","us_adults_with_risk_factor_pct":"74%"}},"named_entities":{"people":[{"name":"Sriram Jambunathan","role":"Head of Marketing & Commercial Strategy, US Vaccines at Sanofi"},{"name":"Christian Portaro","role":"Vice President of Partnerships at USA Pickleball"}],"products":["NUVAXOVID (COVID-19 Vaccine, Adjuvanted)","Serve Up Protection campaign"],"companies":[{"name":"Sanofi","ticker":"SNY","relationship":"issuer / campaign sponsor (filer brand)"},{"name":"USA Pickleball","relationship":"campaign partner; nonprofit national governing body for pickleball"},{"name":"Novavax","relationship":"original licensor of NUVAXOVID; Sanofi is now market authorization holder"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-10T13:06:51.365Z","global_importance":15,"audience_relevance":30,"importance_components":{"tickerTier":"mega-cap pharma (trades as SAN/SNY)","eventGravity":"marketing/education campaign","financialTerms":"none disclosed","issuerAuthored":true,"commercialRelevance":"supports seasonal NUVAXOVID uptake among 65+ cohort","householdBrandBoost":"Sanofi is a household pharma name; COVID/vaccine topic has retail follow-through"}},"durationMs":61493,"modelName":"glm-5.3-flash"}}